Clinical Trial Search

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Overall Survival — 13.43; 7.62 months

Primary: Number of Patients With Treatment Related Serious Adverse Events — 0; 1; 0 Participants

Primary: Complete Response Rate — 2; 15; 4; 3 Participants

Primary: Recurrence Free Survival — 15.6 months

Primary: Overall Survival (OS) — 8.5; 6.7 months — p=<0.0001

Primary: Percentage of Participants Without Disease Progression (Progression-Free Survival) at 6 Months — 78.6; 30 percentage of participants

Primary: Best Overall Response (BOR) — 0; 0; 3; 11 Participants

Primary: Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard — 0.741 proportion of participants

Primary: Progression-free Survival of Patients With Locally Advanced Pancreatic Cancer Treated With Concurrent Gemcitabine, 5-FU, Cetuximab and External Beam Radiation Therapy…

Primary: Local Progression-free Survival (LPFS) — 22.30801 months

Primary: Number of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 4; 23 Participants

Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001

Primary: 12- Month Overall Survival (OS) — 16 Participants

Primary: Rate of Progression Free Survival at 6 Months (24 Weeks) From Initiation of Therapy — 49 percent of patients

Primary: CA 19-9 Normalization — 40; 13.6; 30; 50 Percentage of participants — p=0.235

Primary: Overall Survival Rate at 6 Months — 58 percentage of participants

Primary: Evans Grade Histopathologic Response — 10; 7; 17; 12 number of participants

Primary: Progression-free Survival — 9.2; 8.9 months

Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants

Primary: Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen — 39 Participants

Primary: Response Rate — .125 proportion of participants

Primary: Number of Participants With Dose Limiting Toxicity (DLT ) — 0; 1; 0; 0 Participants

Primary: Number of Participants With Dose-limiting Toxicities — 4; 0; 1 participants

Primary: Kaplan-Meier Estimates for Time to Treatment Failure (TTF) — 9.0 months

Primary: Acute Toxicity Rates of Grade 3 or Greater Gastrointestinal and Hematologic Toxicities (as Raw Percentage) — 13.89; 0.00; 2.78; 0.00 percentage of participants

Primary: Survival in Patients With Pancreatic Adenocarcinoma According to Tissue microRNA Expression — 8.3 months

Primary: Overall Survival — 8.9; 7.6 months

Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants

Primary: Overall Survival (OS) — 210; 171 Days — p=0.1026